(MedPage Today) — LAS VEGAS — Upadacitinib (Rinvoq) showed durable clinical benefit at 1 year among children and adolescents with inflammatory bowel disease (IBD), a single-center study found.
In the retrospective study of 48 patients with…
Source link : https://www.medpagetoday.com/meetingcoverage/ccc/119563
Author :
Publish date : 2026-01-23 21:54:00
Copyright for syndicated content belongs to the linked Source.
